memantine and Drug Withdrawal Symptoms
memantine has been researched along with Drug Withdrawal Symptoms in 24 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Chronic amphetamine use results in anxiety-like states after drug cessation." | 7.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
"Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course." | 7.75 | Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009) |
"The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice." | 7.70 | Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000) |
"The current experiments explore aggression and medial prefrontal cortex (mPFC) glutamate as consequences of withdrawal from intermittent access to EtOH and changes in aggression and mPFC glutamate caused by NMDAR antagonists memantine and ketamine." | 3.81 | Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice. ( DeBold, JF; Holly, EN; Hwa, LS; Miczek, KA; Nathanson, AJ; Newman, EL; Shimamoto, A; Tayeh, JK; Wilens, AR, 2015) |
"Chronic amphetamine use results in anxiety-like states after drug cessation." | 3.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
"Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course." | 3.75 | Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009) |
"The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice." | 3.70 | Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000) |
"Demand for treatments for severe opioid use disorder is increasing worldwide." | 2.66 | Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. ( Fluyau, D; Pierre, CG; Revadigar, N, 2020) |
"Memantine was well tolerated with similar rates of adverse effects between treatment groups." | 2.61 | Adjunctive memantine for opioid use disorder treatment: A systematic review. ( Brown, JN; Elias, AM; Pepin, MJ, 2019) |
"Catatonia is a severe motor syndrome found in approximately 10% of all acute psychiatric hospital admissions." | 1.43 | Catatonia and cannabis withdrawal: A case report. ( Amad, A; Caudron, M; Deheul, S; Geoffroy, PA; Rolland, B; Thomas, P, 2016) |
"Trichostatin A was also observed to exert a synergistic interaction with Ac-DEVD-CHO." | 1.38 | Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. ( Rachamalla, M; Rehni, AK; Singh, N; Tikoo, K, 2012) |
"Memantine was neuroprotective when administered during ethanol withdrawal." | 1.37 | Administration of memantine during ethanol withdrawal in neonatal rats: effects on long-term ethanol-induced motor incoordination and cerebellar Purkinje cell loss. ( Idrus, NM; McGough, NN; Riley, EP; Thomas, JD, 2011) |
"morphine was co-administered with memantine or MK-801." | 1.32 | Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. ( Aguilar, MA; Cauli, O; Maldonado, C; Miñarro, J; Rodríguez-Arias, M, 2003) |
"Treatment with memantine resulted in a complete reversal of these behavioral impairments." | 1.31 | Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. ( Lukoyanov, NV; Paula-Barbosa, MM, 2001) |
Research
Studies (24)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.17) | 18.2507 |
2000's | 11 (45.83) | 29.6817 |
2010's | 11 (45.83) | 24.3611 |
2020's | 1 (4.17) | 2.80 |
Authors
Authors | Studies |
---|---|
Elias, AM | 1 |
Pepin, MJ | 1 |
Brown, JN | 1 |
Fluyau, D | 1 |
Revadigar, N | 1 |
Pierre, CG | 1 |
Romero-Gonzalez, M | 1 |
Shahanaghi, A | 1 |
DiGirolamo, GJ | 1 |
Gonzalez, G | 1 |
Yuanyuan, J | 1 |
Junyan, Z | 1 |
Cuola, D | 1 |
Jingjing, C | 1 |
Yuhui, S | 1 |
Dan, X | 1 |
Wei, D | 1 |
Yongsheng, Z | 1 |
Koltunowska, D | 1 |
Gibula-Bruzda, E | 2 |
Kotlinska, JH | 2 |
Ballard, C | 1 |
Thomas, A | 1 |
Gerry, S | 1 |
Yu, LM | 1 |
Aarsland, D | 1 |
Merritt, C | 1 |
Corbett, A | 1 |
Davison, C | 1 |
Sharma, N | 1 |
Khan, Z | 1 |
Creese, B | 1 |
Loughlin, P | 1 |
Bannister, C | 1 |
Burns, A | 1 |
Win, SN | 1 |
Walker, Z | 1 |
Hwa, LS | 1 |
Nathanson, AJ | 1 |
Shimamoto, A | 1 |
Tayeh, JK | 1 |
Wilens, AR | 1 |
Holly, EN | 1 |
Newman, EL | 1 |
DeBold, JF | 1 |
Miczek, KA | 1 |
Caudron, M | 1 |
Rolland, B | 1 |
Deheul, S | 1 |
Geoffroy, PA | 1 |
Thomas, P | 1 |
Amad, A | 1 |
Marszalek-Grabska, M | 1 |
Jenda, M | 1 |
Gawel, K | 1 |
Kotlinska, J | 1 |
Bochenski, M | 1 |
Kwak, YT | 1 |
Han, IW | 1 |
Suk, SH | 1 |
Koo, MS | 1 |
Idrus, NM | 1 |
McGough, NN | 1 |
Riley, EP | 1 |
Thomas, JD | 1 |
Bisaga, A | 2 |
Sullivan, MA | 1 |
Cheng, WY | 1 |
Carpenter, KM | 1 |
Mariani, JJ | 1 |
Levin, FR | 1 |
Raby, WN | 1 |
Nunes, EV | 1 |
Rehni, AK | 1 |
Singh, N | 1 |
Rachamalla, M | 1 |
Tikoo, K | 1 |
Maldonado, C | 1 |
Cauli, O | 1 |
Rodríguez-Arias, M | 1 |
Aguilar, MA | 1 |
Miñarro, J | 1 |
Sukhotina, IA | 2 |
Zvartau, EE | 2 |
Danysz, W | 3 |
Bespalov, AY | 2 |
Zakharova, E | 1 |
Malyshkin, A | 1 |
Kashkin, V | 1 |
Neznanova, O | 1 |
Sukhotina, I | 1 |
Bespalov, A | 1 |
Thuerauf, N | 1 |
Lunkenheimer, J | 1 |
Lunkenheimer, B | 1 |
Sperling, W | 1 |
Bleich, S | 1 |
Schlabeck, M | 1 |
Wiltfang, J | 1 |
Kornhuber, J | 1 |
Krupitsky, EM | 1 |
Rudenko, AA | 1 |
Burakov, AM | 1 |
Slavina, TY | 1 |
Grinenko, AA | 1 |
Pittman, B | 1 |
Gueorguieva, R | 1 |
Petrakis, IL | 1 |
Krystal, JH | 1 |
Harris, AC | 1 |
Rothwell, PE | 1 |
Gewirtz, JC | 1 |
Popik, P | 2 |
Lukoyanov, NV | 1 |
Paula-Barbosa, MM | 1 |
Comer, SD | 1 |
Ward, AS | 1 |
Kleber, HD | 1 |
Fischman, MW | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence[NCT00476242] | Phase 2/Phase 3 | 82 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Opiate Craving Based on Heroin Craving Scale
Range 0- 100 ( 0= no craving; 100= very strong craving (NCT00476242)
Timeframe: Average of twice weekly assessments for 12 weeks of study or length of participation
Intervention | units on a scale (Mean) |
---|---|
Placebo and Vivitrol | 18.47 |
Memantine and Vivitrol | 15.74 |
Opiate Use Measured by Urine Toxicology Results
Opiate use was qualified by the number of opiate positive urine results. (NCT00476242)
Timeframe: 3x/week during 12 weeks of the trial or study participation
Intervention | Percent of total urine samples (Median) |
---|---|
Memantine and Vivitrol | 9 |
Placebo and Vivitrol | 10 |
Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).
(NCT00476242)
Timeframe: Week 12
Intervention | participants (Number) |
---|---|
Memantine and Vivitrol | 12 |
Placebo and Vivitrol | 19 |
Reviews
2 reviews available for memantine and Drug Withdrawal Symptoms
Article | Year |
---|---|
Adjunctive memantine for opioid use disorder treatment: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Hum | 2019 |
Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.
Topics: Analgesics, Opioid; Excitatory Amino Acid Antagonists; Humans; Ketamine; Memantine; Methadone; Opiat | 2020 |
Trials
5 trials available for memantine and Drug Withdrawal Symptoms
Article | Year |
---|---|
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Over Studies; Dose-Response | 2015 |
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication A | 2011 |
Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?
Topics: Adult; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Memantine; Nicotine; Nicotinic Ag | 2007 |
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
Topics: Adult; Alcoholism; Arousal; Autonomic Nervous System; Depression; Diazepam; Excitatory Amino Acid An | 2007 |
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
Topics: Adult; Dextromethorphan; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Morphin | 2001 |
Other Studies
17 other studies available for memantine and Drug Withdrawal Symptoms
Article | Year |
---|---|
Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cognitive Beh | 2017 |
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway.
Topics: Alcoholism; Animals; Anxiety; Anxiety Disorders; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2018 |
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Topics: Acamprosate; Amphetamine; Animals; Anxiety; Bridged Bicyclo Compounds; Dose-Response Relationship, D | 2013 |
Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice.
Topics: Aggression; Animals; Behavior, Animal; Ethanol; Excitatory Amino Acid Antagonists; Glutamic Acid; Ke | 2015 |
Catatonia and cannabis withdrawal: A case report.
Topics: Adult; Catatonia; Excitatory Amino Acid Antagonists; Humans; Hypnotics and Sedatives; Lorazepam; Mal | 2016 |
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System S | 2016 |
The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Behavior, Animal; Central Nervous System Depressa | 2008 |
Two cases of discontinuation syndrome following cessation of memantine.
Topics: Aged; Alzheimer Disease; Humans; Male; Memantine; Substance Withdrawal Syndrome; Syndrome; Treatment | 2009 |
Administration of memantine during ethanol withdrawal in neonatal rats: effects on long-term ethanol-induced motor incoordination and cerebellar Purkinje cell loss.
Topics: Alcohol Drinking; Animals; Animals, Newborn; Ataxia; Cerebellum; Ethanol; Excitatory Amino Acid Anta | 2011 |
Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Brain; Cysteine Proteinase Inhibitors; Female; Histon | 2012 |
Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Dizocilpine Maleate; Dose-Response Relations | 2003 |
Caffeine withdrawal syndrome in social interaction test in mice: effects of the NMDA receptor channel blockers, memantine and neramexane.
Topics: Animals; Caffeine; Cyclopentanes; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Mal | 2004 |
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Anta | 2004 |
Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia.
Topics: Analgesics, Opioid; Animals; Hyperalgesia; Male; Memantine; Morphine; Morphine Dependence; Naloxone; | 2008 |
Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine.
Topics: Animals; Feeding Behavior; Male; Maze Learning; Memantine; Memory; Morphine; Naloxone; Rats; Rats, W | 1997 |
Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice.
Topics: Aggression; Animals; Cyclopentanes; Excitatory Amino Acid Antagonists; Male; Memantine; Mice; Morphi | 2000 |
Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol.
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Brain; Cognition Disorders; Dizocilpine Maleate; | 2001 |